nocebo

(redirected from Nocebo response)
Also found in: Dictionary.
Related to Nocebo response: Reverse placebo effect

nocebo

 [no-se´bo] (L.)
an adverse, nonspecific side effect occurring in conjunction with a medication but not directly resulting from the pharmacologic action of the medication.

no·ce·bo

(nō-sē'bō),
An unpleasant effect attributable to administration of a placebo.
[L. I shall harm, fr. noceo, to harm, by analogy with placebo, I shall please]

nocebo

/no·ce·bo/ (no-se´bo) [L.] an adverse, nonspecific side effect occurring in conjunction with a medication but not directly resulting from the pharmacologic action of the medication.

nocebo

(nō-sē′bō)
n. pl. noce·bos or noce·boes
A substance that causes undesirable side effects as a result of a patient's perception that it is harmful rather than as a result of a causative ingredient.

nocebo

[nose′bo]
an adverse, nonspecific side effect occurring in conjunction with a medication but not directly resulting from the pharmacological action of the medication.

nocebo

A negative placebo effect, which may occur when patients in a clinical trial of a drug therapy recognise (or think they recognise) that they are getting a placebo—i.e., not receiving therapy—and fare worse due to the effect of negative suggestibility.

nocebo

Clinical trials A negative placebo effect that may occur when Pts in a clinical trial of a drug therapy recognize–or think they recognize that they are getting a placebo–ie, not receiving therapy, and fare worse due to the effect of negative suggestibility. Cf Placebo.

no·ce·bo

(nō-sē'bō)
An unpleasant effect attributable to administration of a placebo.
[L. I shall harm, fr. noceo, to harm, by analogy with placebo, I shall please]

nocebo (nōˑ·sē·bō),

n a negative, harmful placebo effect. See also placebo and placebo effect.
References in periodicals archive ?
This could lead to worsening of illness, known as the nocebo response .
On average, about 25% of people in trials experience some type of nocebo response, with the most common being headaches, drowsiness and weakness.
The trials of the disease-modifying drugs showed the very high nocebo response of 74%.